Abstract
Human intravenous immunoglobulins (hIVIgs) are used in two broad categories of diseases: immunodeficiency and autoimmunity. Among the immune-mediated diseases hIVIgs are of benefit in idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and dermatomyositis. Chronic idiopathic pericarditis (CIP) is a chronic disease of unknown origin characterized by recurrent episodes of pericardial inflammation. The cause of the recurrence is unknown, although in some cases it may be traced to a viral infection and to the presence of antimyocardial antibodies. Since a viral infection can induce an autoimmune process through a mechanism of molecular mimicry, and since the optimal therapy for prevention of the recurrences has not been established, we reasoned that treatment with hIVIgs could be beneficial in our patients unresponsive to previous immunosuppressive therapies. We describe four patients affected by CIP treated with monthly high-dose hIVIgs (0.4 g/kg daily for 5 consecutive days) for five times followed by administration every 2 months. Three of the four patients could permanently discontinue steroid therapy and are still in remission after years of follow-up. Our experience suggests that hIVIgs therapy may be a useful and safe treatment for CIP in steroid-dependent patients.
Similar content being viewed by others
References
Spodick DH (1992) Disease of the pericardium. In: Pamley WW, Chatterjee K (eds) Cardiology. Lippincott, Philadelphia, pp 1–34
Granel B, Serratrice J, Rey J, Pache X, et al. (2001) Is chronic or recurrent idiopathic an autonomous inflammatory disease? Rev Med Interne 22:1204–1212
Pankuweit S, Wadlich A, Meyer E, Portig I, Hufnagel G (2000) Cytokine activation in pericardial fluids in different forms of pericarditis. Herz 25:748–754
Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, Puccetti A (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6:1183–1186
Shoenfeld Y (2003) Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome unravelled. Trends Immunol 24:2–4
Millaire A, de Groote P, Decoulx E, Goullard L, Ducloux G (1994) Treatment of recurrent pericarditis with colchicine. Eur Heart J 15:120–124
Raatikka M, Pelkonen PM, Karjalainen J, Jokinen EV (2003) Recurrent pericarditis in children and adolescents: report of 15 cases. J Am Coll Cardiol 42:759–764
Bruton OC (1952) Agammaglobulinemias. Pediatrics 9:722–728
Buckley RH, Shiff RI (1991) The use of intravenous immune globulin in immunodeficiency disease. N Engl J Med 325:110–117
Schwartz SA (1990) Intravenous immunoglobulin for autoimmune disorders. J Clin Immunol 10:81–89
Pyne D, Ehrestein M, Morris V (2002) The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 41:367–374
Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L (2002) Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs 16:47–55
Ballow M (1997) Mechanism of action of intravenous immune serum globulin in autoimmune and inflammatory disease. J Allergy Clin Immunol 100:151–157
Zhiya Yu, Lennon VA (1993) Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 40:227–228
Kazatchkine MD, Kaveri SV (2001) Immunomodulation of the autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755
Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486
Sacher RA, IVIG Advisory Panel (2001) Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108:S139–S146
Tona F, Bellotto F, Laveder F, Meneghin A, Sinagra GF, Marcolongo R (2003) Efficacy of high-dose intravenous immunoglobulins in two patients with idiopathic recurrent pericarditis refractory to previous immunosuppressive treatment. Ital Heart J 4:64–68
Adler Y, Guindo J, Rodriguez de la Serna A, et al. (1998) Colchicine treatment for recurrent pericarditis. Circulation 97:2183–2285
Fowler NO (1990) Recurrent pericarditis. Cardiol Clin 8:621–626
Ryan ME, Webster ML, Statler JD (1996) Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr 35:23–31
Krause I, Wu R, Sherer Y, et al. (2002) In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations—a potential role for adjuvant intravenous immunoglobulin therapy in infectious disease. Transfus Med 12:133–139
Takeda Y, Yasuda S, Miyazaki S, Daikoku S, Nakatani S, Nonogi H (1998) High-dose immunoglobulin G therapy for fulminant myocarditis. Jpn Circ J 62:871–872
Portugese S, Amital H, Tenenbaum A, et al. (1998) Clinical characteristics of ruptured chordae tendineae in hospitalized patients: primary tear versus infective endocarditis. Clin Cardiol 21:813–816
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peterlana, D., Puccetti, A., Simeoni, S. et al. Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol 24, 18–21 (2005). https://doi.org/10.1007/s10067-004-0959-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-0959-7